EA201291133A1 - Антитела, обладающие пониженной иммуногенностью в организме человека - Google Patents

Антитела, обладающие пониженной иммуногенностью в организме человека

Info

Publication number
EA201291133A1
EA201291133A1 EA201291133A EA201291133A EA201291133A1 EA 201291133 A1 EA201291133 A1 EA 201291133A1 EA 201291133 A EA201291133 A EA 201291133A EA 201291133 A EA201291133 A EA 201291133A EA 201291133 A1 EA201291133 A1 EA 201291133A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
human body
reduced immunogenicity
humans
relates
Prior art date
Application number
EA201291133A
Other languages
English (en)
Inventor
Расселл П. Ротер
Пол П. Тамберини
Original Assignee
Алексион Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алексион Фармасьютикалз, Инк. filed Critical Алексион Фармасьютикалз, Инк.
Publication of EA201291133A1 publication Critical patent/EA201291133A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)

Abstract

Изобретение относится к рекомбинантным антителам, которые после введения человеку проявляют низкий уровень иммуногенности в организме человека. Изобретение также относится к способам получения антител. Рекомбинантные антитела можно получить, например, из нечеловеческих (например, мышиных) донорных антител или из химерных или гуманизированных антител, которые при длительном введении человеку заведомо вызывают или могут вызвать ответ, связанный с образованием нейтрализующих антител в организме человека.
EA201291133A 2010-04-30 2011-04-29 Антитела, обладающие пониженной иммуногенностью в организме человека EA201291133A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33026110P 2010-04-30 2010-04-30
PCT/US2011/034598 WO2011137362A1 (en) 2010-04-30 2011-04-29 Antibodies having reduced immunogenicity in a human

Publications (1)

Publication Number Publication Date
EA201291133A1 true EA201291133A1 (ru) 2013-04-30

Family

ID=44861933

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201291133A EA201291133A1 (ru) 2010-04-30 2011-04-29 Антитела, обладающие пониженной иммуногенностью в организме человека

Country Status (13)

Country Link
US (1) US20140206849A1 (ru)
EP (1) EP2563812A4 (ru)
JP (1) JP2013531476A (ru)
KR (1) KR20130098161A (ru)
CN (2) CN103108885A (ru)
BR (1) BR112012027917A2 (ru)
CA (1) CA2798120A1 (ru)
CO (1) CO6660464A2 (ru)
EA (1) EA201291133A1 (ru)
IL (1) IL222691A0 (ru)
MX (1) MX2012012689A (ru)
SG (1) SG185107A1 (ru)
WO (1) WO2011137362A1 (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
MX369784B (es) 2007-09-26 2019-11-21 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
DK2708559T3 (en) 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
US9011852B2 (en) 2010-04-30 2015-04-21 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies
TW201241008A (en) * 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
RS57827B1 (sr) 2012-02-15 2018-12-31 Novo Nordisk As Antitela koja vezuju protein 1 prepoznavanja peptidoglikana
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
LT2814844T (lt) 2012-02-15 2017-10-25 Novo Nordisk A/S Antikūnai, kurie jungiasi ir blokuoja ekspresuotą ant mieloidinių ląstelių inicijuojantį receptorių 1 (trem-1)
GB201220242D0 (en) * 2012-11-09 2012-12-26 Fusion Antibodies Ltd Antibody
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
MX2017000484A (es) 2014-07-17 2017-05-01 Novo Nordisk As Mutagenesis dirigida al sitio anticuerpos receptor desencadenante expresado en las celulas mieloides de tipo 1 (trem-1) para reducir la viscosidad.
WO2016061066A1 (en) 2014-10-15 2016-04-21 Alexion Pharmaceuticals, Inc. Methods of replicating a large scale eculizumab production cell culture
EP3207132B1 (en) 2014-10-15 2019-07-31 Alexion Pharmaceuticals, Inc. Methods of shifting an isoelectric profile of a protein product and uses thereof
PL3221359T3 (pl) 2014-11-17 2020-11-16 Regeneron Pharmaceuticals, Inc. Sposoby leczenia nowotworów przy użyciu dwuswoistego przeciwciała CD3XCD20
LT3233921T (lt) 2014-12-19 2021-12-10 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antikūnai ir panaudojimo būdai
AU2016242866B2 (en) 2015-03-30 2021-06-03 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to FC gamma receptors
NL2014935B1 (en) * 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Ｉｌ−８関連疾患の治療用又は予防用組成物
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
EP4218813A3 (en) 2017-07-27 2023-08-16 Alexion Pharmaceuticals, Inc. High concentration anti-c5 antibody formulations
EA202092302A1 (ru) 2018-04-02 2021-02-02 Бристол-Майерс Сквибб Компани Антитела к trem-1 и их применения
CA3110513A1 (en) 2018-08-31 2020-03-05 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
WO2021005607A1 (en) * 2019-07-09 2021-01-14 National Institute For Biotechnology In The Negev Ltd. Antibodies with reduced immunogenicity
CN112210005B (zh) * 2019-07-11 2024-03-26 京天成生物技术(北京)有限公司 低免疫原性低adcc/cdc功能的抗c5人源化单抗及其应用
WO2022035888A2 (en) * 2020-08-10 2022-02-17 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Sars-cov-2-neutralizing antibodies, biomarkers to predict protection from re-infection, and high efficiency antibody screening methods
US20240141061A1 (en) 2021-01-12 2024-05-02 Sg Medical Inc Novel antibody against cd55 and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
WO2006117910A1 (ja) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
US20080071063A1 (en) * 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
EP3381445B1 (en) * 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration

Also Published As

Publication number Publication date
MX2012012689A (es) 2013-12-16
JP2013531476A (ja) 2013-08-08
BR112012027917A2 (pt) 2017-11-28
KR20130098161A (ko) 2013-09-04
CN104402997A (zh) 2015-03-11
EP2563812A4 (en) 2016-01-13
SG185107A1 (en) 2012-12-28
IL222691A0 (en) 2012-12-31
CA2798120A1 (en) 2011-11-03
CN103108885A (zh) 2013-05-15
WO2011137362A1 (en) 2011-11-03
EP2563812A1 (en) 2013-03-06
CO6660464A2 (es) 2013-04-30
US20140206849A1 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
EA201291133A1 (ru) Антитела, обладающие пониженной иммуногенностью в организме человека
CY1123215T1 (el) Πολυνουκλεοτιδια τα οποια κωδικοποιουν αντισωματα τρωκτικων με ανθρωπινους ιδιοτυπους και ζωα τα οποια διαθετουν αυτα
NI201800052A (es) Anticuerpos que neutraliza el virus respiratorio sincitial humano
MX2013001845A (es) Polipetidos que enlazan miostatina, composiciones y metodos.
WO2015089492A3 (en) Dna antibody constructs and method of using same
MX2021015971A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
NZ704584A (en) Liquid stable virus vaccines
BR112018008901A2 (pt) formulações subcutâneas de anticorpos anti-cd 38 e seus usos
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
MX2015012737A (es) Vacunas de virus bovino liquidas estables.
MX2013011012A (es) Cristales de anticuerpos anti-esclerostina y formulaciones de los mismos.
MX2023009421A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
MX2023006415A (es) Anticuerpos, usos y metodos.
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
PH12015500890A1 (en) Vaccine for preventing porcine edema disease
MX2019007252A (es) Metodos y composiciones para vacunas del virus del dengue.
TR201910413T4 (tr) Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler.
WO2014194053A3 (en) Carbohydrate compounds for nutritional and therapeutic use
WO2014188212A3 (en) Treatment and prevention of malaria
ECSP18039827A (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
TN2013000064A1 (en) Antibodies that bind myostatin, compositions and methods
EA201992003A1 (ru) Применение антител к ctla-4 с повышенной adcc для усиления иммунного ответа на вакцину